Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Nirali N. Shah(National Institutes of Health), Guenther Koehne(Baptist Hospital of Miami), Muhammad Umair Mushtaq(Health Innovations (United States)), Hyung C. Suh(Science Applications International Corporation (United States)), Rupa Narayan(Stanford University), Abhinav Deol(Wayne State University), Lori Muffly(Stanford University), Brian McClune(University of Minnesota Medical Center), John F. DiPersio(Washington University in St. Louis), Jennifer Whangbo(Boston Children's Hospital), Sritama Nath(University of North Carolina at Charlotte), Gregory A. Yanik(University of Michigan), Jacques Azzi(Icahn School of Medicine at Mount Sinai), Divya Koura(University of California San Diego)
Cited by 12
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k